Navigating the Final Stretch for Obicetrapib in High-Risk LDL-C Reduction

NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing obicetrapib, an oral, low-dose CETP inhibitor, for the treatment of cardiovascular disease. The company's primary objective is to address the substantial residual risk in patients with, or at high risk for, cardiovascular events who have elevated LDL-C. Obicetrapib is designed to be administered once daily as a monotherapy or in combination with other lipid-lowering agents, including statins and ezetimibe.

The company generates no current revenue and operates solely as a research and development entity. Its primary source of value creation is the clinical development of its lead asset, with a pipeline that includes combinations of obicetrapib with ezetimibe. NewAmsterdam's target customers are not end-patients but rather the medical community, specifically cardiologists and lipidologists, alongside payers and health systems that would adopt and reimburse the therapy.

NewAmsterdam is a multinational organization with operations in both the U.S. and Europe, reflecting its global development strategy. As of the latest data, the company has a market capitalization of $2.9B and is funded by a combination of equity financing and strategic partnerships, including a significant investment from a major Asian pharmaceutical group. The company's scientific and clinical operations are led by a team with extensive experience in cardiovascular drug development, and its late-stage trials are being conducted across hundreds of clinical sites worldwide.

• Near-Term (0-12 Months): The primary growth catalyst is the release of top-line results from the Phase 3 PREVAIL cardiovascular outcomes trial. A positive result, showing a statistically significant reduction in major adverse cardiovascular events (MACE), is the key to unlocking the drug's commercial potential. Following this, the company would engage in regulatory filings (NDA/MAA) with the FDA and EMA, with potential approval and launch expected in the following 12-24 months. The near-term stock performance is entirely tied to these events.
• Medium-Term (1-3 Years): Assuming a successful readout and regulatory approval, the growth outlook shifts to commercial execution. The company's ability to secure a strategic partner for commercialization, build a specialty sales force, and secure favorable reimbursement will be critical. The potential label expansion to include broader ASCVD patient populations and the launch of an obicetrapib/ezetimibe combination pill could further expand the addressable market and drive revenue growth. Peak sales could be achieved within 5-7 years post-launch, given the large patient population and the drug's potent efficacy.

Note: Figures for 2023A and 2024A are estimates. 2025E-2027E are illustrative projections based on a successful PREVAIL readout and a 2026 launch.

The company's financial profile is typical of a late-stage biotech, characterized by significant R&D investment and no revenue. The historical EPS of -$2.16 is consistent with this pre-commercial phase. The near-term financials will be driven by the costs of the PREVAIL trial and preparation for regulatory submission. Post-approval, the model shifts dramatically, with revenue beginning to flow in 2027E as the commercial infrastructure is established. The key financial risk is the need for additional capital to fund the launch, which would likely come in the form of a partnership or dilutive financing, impacting future EPS.

The market for lipid-lowering therapies is substantial and growing, estimated at over $30 billion annually. This growth is driven by an aging population, increasing prevalence of cardiovascular disease, and updated clinical guidelines that recommend more aggressive LDL-C targets. The market is dominated by statins, but there is a significant and growing segment of patients who require additional therapies. This includes PCSK9 inhibitors (a class of injectable biologics) and, more recently, oral options like bempedoic acid.

NewAmsterdam's obicetrapib, if approved, would compete in the oral, non-statin add-on market. Its primary advantages are its potent efficacy (greater LDL-C reduction than bempedoic acid) and its oral administration (more convenient than injectable PCSK9 inhibitors). Key competitors in this space include:

Obicetrapib's potential to offer oral efficacy comparable to injectables positions it uniquely. However, it will need to demonstrate not just efficacy but also a definitive safety advantage in the PREVAIL outcomes trial to convince physicians and payers. The high short interest in NAMS suggests that a portion of the market is skeptical of the drug's ability to show a positive outcomes benefit or a clear safety signal, making the competitive positioning contingent on trial success.

Our valuation of NewAmsterdam is contingent on the outcome of the PREVAIL trial. We employ a risk-adjusted net present value (rNPV) model for the lead asset, which we believe is more appropriate than a standard DCF given the binary nature of clinical development.

• rNPV Model Assumptions: We assign a 65% probability of success (POS) to the PREVAIL trial, reflecting the strong efficacy seen in earlier trials but acknowledging the historical challenges of the CETP class. In a success scenario, we model obicetrapib to launch in 2027, achieve a peak market share of 10% in its target indication, and generate peak annual sales of $2.5B by 2032. We apply a 15% discount rate to account for the biotech risk profile.
• Comparable Company Analysis: Given the lack of revenue, we use EV/Sales multiples for revenue-generating comparables and a more qualitative approach for pre-revenue peers. The table below shows illustrative valuations based on a successful launch scenario.

Using our rNPV model, a successful PREVAIL outcome supports a base-case valuation of approximately $35 per share. However, in a failure scenario, the stock would likely trade down to its cash value, which we estimate at $5-6 per share. The current price of $24.03 implies that the market is pricing in a significant probability of success but with a wide range of potential outcomes. Our price target of $35.00 reflects a successful readout and successful commercialization, representing an upside of approximately +46% from the current price.

• Clinical Trial Failure: The most significant risk is a negative or inconclusive result from the PREVAIL cardiovascular outcomes trial. Historical data from other CETP inhibitors (e.g., torcetrapib, evacetrapib) have shown that despite robust lipid modifications, they failed to demonstrate a reduction in cardiovascular events or were associated with off-target toxicity. A similar outcome for obicetrapib would be value-destructive.
• Safety Signal: While the drug has a clean safety profile to date, the larger and longer PREVAIL trial could uncover rare or long-term safety issues. Any signal of concern, such as an increase in blood pressure or adverse effects on adrenal function, could lead to regulatory rejection or a restricted label, severely limiting its commercial potential.
• Commercial Execution and Competition: Even with a successful trial, the launch of obicetrapib will face significant competition from entrenched players like Amgen and Regeneron, who have established relationships with cardiologists and robust patient support programs. NewAmsterdam's lack of a commercial infrastructure and the potential for a lengthy payer negotiation process could slow the drug's adoption and limit peak sales.
• Financing and Dilution Risk: The company's cash runway is not sufficient to fund a full commercial launch. Post-PREVAIL, the company will need to secure additional capital through a partnership, debt financing, or an equity offering. Any of these options could significantly dilute existing shareholders or cede substantial economic value to a partner.
• Regulatory and Reimbursement Hurdles: The FDA and EMA may require additional data or impose restrictions on the initial label. Furthermore, securing favorable reimbursement from payers will be critical, as they may demand evidence of outcomes benefits and cost-effectiveness compared to cheaper generic statins or other alternatives. Failure to secure adequate reimbursement would limit the drug's addressable patient population.